Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.044
- Book/Share 16.3757
- PB 1.5787
- Debt/Equity 0.665
- CurrentRatio 1.2822
- ROIC 0.099
- MktCap 146520683615.0
- FreeCF/Share 1.8252
- PFCF 14.1211
- PE 14.9173
- Debt/Assets 0.2957
- DivYield 0.0667
- ROE 0.1091
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | PFE | UBS | -- | Neutral | -- | $25 | Jan. 7, 2026 |
| Resumed | PFE | Citigroup | -- | Neutral | -- | $26 | Dec. 2, 2025 |
| Initiation | PFE | Scotiabank | -- | Sector Outperform | -- | $30 | Nov. 13, 2025 |
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
Published: February 04, 2026 by: The Motley Fool
Sentiment: Positive
Eli Lilly has leading products in the GLP-1 space, with plans to bring pill versions of its weight loss shots to market. Pfizer is playing catch-up in the GLP-1 space, but it has a long history of innovation.
Read More
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Read More
Pfizer: Messy Q4 Earnings Mask An Improving Business
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer Inc. earns a Buy rating as the market overreacts to Q4's non-cash loss and conservative 2026 guidance, overlooking underlying operational strength. Excluding COVID-19 products, PFE posted 9% YoY growth, driven by oncology, signaling a successful pivot away from declining pandemic franchises. Patent cliffs—Xeljanz in 2026, Eliquis in 2028—pose risks, but PFE is aggressively advancing a 102-candidate pipeline targeting oncology, obesity, and migraine.
Read More
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.
Read More
Silver Surges Over 15%; Pfizer Earnings Top Views
Published: February 03, 2026 by: Benzinga
Sentiment: Neutral
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.
Read More
Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Negative
Pfizer reported Q4 and FY2025 revenues and EPS above expectations, but core revenues declined due to falling COVID product sales. Despite a 6.5% dividend yield and low valuation multiples, PFE remains a value trap as share price performance lags and patent expiries loom. Recent M&A, including Seagen and Metsera, must deliver as COVID windfall fades and major assets like Eliquis and Prevnar approach patent cliffs.
Read More
Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways
Published: February 03, 2026 by: CNBC Television
Sentiment: Neutral
Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.
Read More
2 Pharma Stocks React to Quarterly Results, Guidance
Published: February 03, 2026 by: Schaeffers Research
Sentiment: Negative
Pfizer Inc (NYSE:PFE) shares are down 3.2% to trade at $25.40 at last check, despite surpassing earnings and revenue expectations for the fourth quarter.
Read More
Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Pfizer beats Q4 profit estimates despite COVID-19 sales decline
Published: February 03, 2026 by: Proactive Investors
Sentiment: Neutral
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported fourth-quarter and full-year 2025 results on Tuesday, exceeding analyst expectations on adjusted earnings even as sales of its COVID-19 products fell. The pharmaceutical company's beat on profit wasn't enough to offset concerns about declining COVID-19 revenue and future growth uncertainties, with shares dropping 4.3% on Tuesday morning in New York.
Read More
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.63 per share a year ago.
Read More
Pfizer says once-a-month weight-loss drug works as it forecasts profit decline
Published: February 03, 2026 by: Market Watch
Sentiment: Neutral
Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration's policies on pricing and tariffs.
Read More
Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand
Published: February 03, 2026 by: WSJ
Sentiment: Negative
Pfizer reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline.
Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Published: February 03, 2026 by: CNBC
Sentiment: Positive
Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
Read More
Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.
Published: February 03, 2026 by: Barrons
Sentiment: Negative
Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.
Read More
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
Published: February 03, 2026 by: CNBC
Sentiment: Neutral
Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Read More
Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial
Published: February 03, 2026 by: Reuters
Sentiment: Positive
Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial.
Read More
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--PFE Q4 2025 Earnings Release.
Read More
Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study had two objectives: (1) to demonstrate PF'3944 could achieve continued weight loss when switching from weekly to monthly subcutaneous injections and maintain its e.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Read More
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral
Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 billion and 57 cents per share, respectively.
Read More
Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Negative
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer (PFE) remains a 'Buy' ahead of its fiscal Q1 2027 earnings, with the stock deeply discounted and consensus estimates overly pessimistic. LOE headwinds are significant but phased, while cost savings ($7.7B by 2027) and pipeline catalysts offer margin and revenue offsets. Pipeline momentum—especially in obesity, oncology, and vaccines—could drive narrative shifts and repricing if key 2026 readouts succeed.
Read More
Novavax Stock Pops After Pfizer Licensing Agreement
Published: January 20, 2026 by: Schaeffers Research
Sentiment: Positive
Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing agreement -- worth up to $500 million, including a $30 million upfront payment -- with Pfizer (PFE) for use of its Matrix-M adjuvant for up to two disease areas.
Read More
Which Pharma Stock Stands Taller Right Now: LLY or PFE?
Published: January 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case against peers.
Read More
MoneyShow's Best Investment Ideas For 2026: Part 7
Published: January 19, 2026 by: Seeking Alpha
Sentiment: Neutral
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 7 of this series includes Pfizer, Philip Morris International, Platinum Group Metals, Prologis and QuickLogic Corp.
Read More
What to Expect From Pfizer's Non-Oncology Business in Q4?
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.
Read More
Pfizer: Rebound Has Just Started
Published: January 16, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial stability, reinforcing confidence in PFE's outlook. PFE's substantial 6.7% forward dividend yield appears secure, offering attractive income in a volatile market.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000